Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Vontobel Holding Ltd.

Vontobel Holding Ltd. lowered its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 42.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,442 shares of the company's stock after selling 6,148 shares during the quarter. Vontobel Holding Ltd.'s holdings in Neurocrine Biosciences were worth $1,152,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the business. Creative Planning boosted its stake in shares of Neurocrine Biosciences by 12.3% during the third quarter. Creative Planning now owns 12,999 shares of the company's stock valued at $1,498,000 after purchasing an additional 1,426 shares during the period. Blue Trust Inc. lifted its holdings in Neurocrine Biosciences by 171.9% during the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company's stock valued at $40,000 after buying an additional 220 shares in the last quarter. Raymond James & Associates boosted its position in Neurocrine Biosciences by 4.3% in the 3rd quarter. Raymond James & Associates now owns 62,446 shares of the company's stock valued at $7,195,000 after buying an additional 2,552 shares during the period. Stanley Laman Group Ltd. grew its stake in Neurocrine Biosciences by 36.8% in the 3rd quarter. Stanley Laman Group Ltd. now owns 37,531 shares of the company's stock worth $4,324,000 after acquiring an additional 10,088 shares in the last quarter. Finally, Lecap Asset Management Ltd. increased its position in shares of Neurocrine Biosciences by 42.6% during the third quarter. Lecap Asset Management Ltd. now owns 8,072 shares of the company's stock worth $930,000 after acquiring an additional 2,412 shares during the period. Institutional investors own 92.59% of the company's stock.

Analyst Ratings Changes

Several brokerages recently issued reports on NBIX. Deutsche Bank Aktiengesellschaft initiated coverage on Neurocrine Biosciences in a research note on Tuesday, February 11th. They issued a "hold" rating and a $138.00 price objective on the stock. Royal Bank of Canada dropped their price target on Neurocrine Biosciences from $154.00 to $148.00 and set a "sector perform" rating on the stock in a research report on Friday, February 7th. StockNews.com lowered Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a research note on Tuesday. Bank of America lowered their price objective on shares of Neurocrine Biosciences from $184.00 to $179.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Finally, Canaccord Genuity Group cut their target price on shares of Neurocrine Biosciences from $172.00 to $163.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. Five investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Neurocrine Biosciences has a consensus rating of "Moderate Buy" and a consensus target price of $166.90.

Insider Activity at Neurocrine Biosciences

In other news, Director Kevin Charles Gorman sold 2,707 shares of the firm's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $152.92, for a total value of $413,954.44. Following the completion of the transaction, the director now directly owns 517,030 shares in the company, valued at $79,064,227.60. This trade represents a 0.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Ingrid Delaet sold 1,091 shares of the company's stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $135.00, for a total value of $147,285.00. Following the completion of the sale, the insider now owns 2,507 shares in the company, valued at approximately $338,445. This represents a 30.32 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 236,600 shares of company stock valued at $34,348,261 in the last ninety days. Company insiders own 4.30% of the company's stock.

Neurocrine Biosciences Trading Up 3.9 %

Shares of NBIX stock traded up $4.58 during trading hours on Friday, reaching $120.69. 1,960,426 shares of the company's stock were exchanged, compared to its average volume of 1,340,164. Neurocrine Biosciences, Inc. has a 1 year low of $110.95 and a 1 year high of $157.98. The stock has a market cap of $12.03 billion, a PE ratio of 36.68, a PEG ratio of 0.76 and a beta of 0.33. The stock's fifty day moving average price is $136.75 and its two-hundred day moving average price is $129.71.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. On average, equities analysts expect that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.